When the guardian sleeps: Reactivation of the p53 pathway in cancer by Merkel, O et al.
       
Content  
Introduction ................................................................................................................................. 3	  
1. Targeting Mutant Forms of p53 ......................................................................................... 7	  
1.1. Small Molecules Targeting Mutant p53 .................................................................... 7	  
1.2 Restoration of Mutant p53 with Zinc ........................................................................ 11	  
1.3 Proteosomal Depletion of Mutant p53 ..................................................................... 12	  
1.4 Targeting Downstream Pathways Activated by Mutant p53 .............................. 14	  
2. Reactivation of WT p53 ...................................................................................................... 15	  
2.1 MDM2 and/or MDMX Inhibitors .................................................................................. 16	  
2.1.1 MDM2 inhibitors: peptides. ................................................................................. 17	  
2.1.2 MDM2 inhibitors: small molecules. ................................................................... 18	  
2.1.3 MDMX inhibitors. .................................................................................................... 21	  
2.2 Targeting p53 Upstream Regulators ........................................................................ 23	  
3. Vaccination and Gene Therapy Approaches ............................................................... 24	  
3.1 TP53 Vaccination ........................................................................................................... 24	  
3.2 Gene Therapy Strategies ............................................................................................. 25	  
3.3 TP53 Oncolytic Viruses ............................................................................................... 26	  
3.4 MicroRNA based strategies ........................................................................................ 27	  
4. Outlook ................................................................................................................................... 29	  
References ................................................................................................................................. 53	  
Running head: DRUG DISCOVERY TARGETING THE P53 PATHWAY 1 
When the guardian sleeps: Reactivation of the 
p53 pathway in cancer 
Olaf Merkela,g, Ninon Taylorb, Nicole Prutscha, Philipp Staberc, Richard Moriggld,e 
Suzanne Turnerf,g, Lukas Kennera,d,g,h 
a Department of Clinical Pathology, Medical University Vienna, Waehringer Guertel 18-
20, 1090 Vienna, Austria.  
b Department of Internal Medicine III with Hematology, Medical Oncology, 
Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Laboratory of 
Immunological and Molecular Cancer Research Laboratory of Immunological and 
Molecular Cancer Research, Paracelsus Medical University, Salzburg, Austria 
c Division of Hematology and Hemostaseology, Comprehensive Cancer Centre Vienna, 
Medical University of Vienna, 1090 Vienna, Austria 
d Ludwig Boltzmann Institute for Cancer Research, Waehringerstrasse 13a, 1090 
Vienna, Austria 
e Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna 
and Medical University of Vienna, Austria 
f Department of Pathology, University of Cambridge, Lab Block Level 3, Box 231, 
Addenbrooke’s Hospital, Cambridge CB20QQ, UK,  
g European Research Initiative for ALK-related malignancies. 
h Institute of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 
Veterinaerplatz 1, Vienna, Austria; 
 
Corresponding authors: Olaf Merkel, Department of Clinical Pathology, Medical 
University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria  
Email: olaf.merkel@meduniwien.ac.at  
Lukas Kenner, Department of Clinical Pathology, Medical University Vienna, 
Waehringer Guertel 18-20, 1090 Vienna, Austria,  
Email: lukas.kenner@meduniwien.ac.at 
 
DRUG DISCOVERY TARGETING THE P53 PATHWAY 2 
 
Abstract 
The p53 tumor suppressor is inactivated in most cancers, thus suggesting that loss of 
p53 is a prerequisite for tumor growth.  Therefore, its reintroduction through different 
means bears great clinical potential.  After a brief introduction to current knowledge of 
p53 and its regulation by the ubiquitin-ligases MDM2/MDMX and post-translational 
modifications, we will discuss small molecules that are able to reactivate specific, 
frequently observed mutant forms of p53 and their applicability for clinical purposes.  
Many malignancies display amplification of MDM genes encoding negative regulators of 
p53 and therefore much effort to date has concentrated on the development of 
molecules that inhibit MDM2, the most advanced of which are being tested in clinical 
trials for sarcoma, glioblastoma, bladder cancer and lung adenocarcinoma. These will 
be discussed as will recent findings of MDMX inhibitors: these are of special importance 
as it has been shown that cancers that become resistant to MDM2 inhibitors often 
amplify MDM4.  Finally, we will also touch on gene therapy and vaccination approaches; 
the former of which aims to replace mutated TP53 and the latter whose goal is to 
activate the body’s immune system toward mutant p53 expressing cells.  Besides the 
obvious importance of MDM2 and MDMX expression for regulation of p53, other 
regulatory factors should not be underestimated and are also described.  Despite the 
beauty of the concept, the past years have shown that many obstacles have to be 
overcome to bring p53 reactivation to the clinic on a broad scale, and it is likely that in 
most cases it will be part of a combined therapeutic approach.  However, improving 
current p53 targeted molecules and finding the best therapy partners will clearly impact 
the future of cancer therapy. 
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Introduction 
The tumor suppressor protein p53, also called “the guardian of the genome”, 
protects the genome by responding to cellular stress and DNA damage; promoting 
transient cell cycle arrest enabling DNA repair, an irreversible cell cycle arrest called 
senescence or cell death depending on the type of stress and the cellular environment 
(Vogelstein, Lane, & Levine, 2000).  It therefore follows that the p53 protein-coding 
gene TP53 is the most frequently mutated gene in human cancers mostly through point 
mutations in exons 5-10, whereby amino acid substitutions lead to disruption of p53 
binding to DNA and subsequent loss of function (LOF).  Hence, cells in the process of 
transformation harboring mutant TP53 can develop an unstable genome, evade 
apoptosis and may finally develop into malignancies.  Therefore, it is not surprising that 
TP53 mutated or deleted tumor cells are resistant to many chemotherapeutic agents 
since the basis of their efficacy is DNA damage leading to activation of intact p53.  As 
such, mutated TP53 is found in over 50% of all human cancers but the incidence of p53 
mutatants varies significantly between cancer types, ranging from 95% in uterine 
carcinomas to 5% in cervical or thyroid cancer (www.cbioportal.org).  However, there is 
also growing evidence that some mutant forms of p53 lead not only to loss of wild-type 
(WT) p53 tumor suppressive function but also display gain of function (GOF) properties 
that infer a survival advantage during tumor evolution (G. Liu et al., 2000; Xiong et al., 
2014).  For example, mice lacking expression of p53 as a result of gene ‘knock-out’ 
show a different disease phenotype to mutant p53 ‘knock-in’ mice whereby the 
presence of mutant p53 enhances tumor metastasis (G. Liu et al., 2000; Xiong et al., 
2014).  Consequently, not all mutations detected in p53, in tumor cells are equal in their 
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consequences to p53 function; as mentioned above, some mutations lead to LOF, 
others to GOF and some act in a dominant-negative manner over the WT protein when 
present in heterozygosity. 
  Moreover, p53 is highly regulated by an intricate network of modifier proteins 
enabling or inhibiting p53 functions.  These interdependent signaling pathways provide 
many, sometimes unexpected, targets for therapeutic intervention.  Central to the 
function of p53 is its transcription factor activity whereby it binds as a tetramer to DNA at 
the repetitive consensus binding site sequence (CATGXXXXXCATG) (Cui, Kerby, 
McDuff, Ye, & Turner, 2009; Nikulenkov et al., 2012).  Currently, more than a hundred 
target genes have been described (Riley, Sontag, Chen, & Levine, 2008) but the most 
studied include pro-apoptotic BH3 only proteins (e.g. Puma, Bax, Noxa), the cell cycle 
inhibitor p21, death receptors (e.g. Fas) and non-coding RNAs like miR-34a (Asslaber 
et al., 2010).  Regulation of p53 activity under physiological conditions is largely 
controlled by proteosomal-mediated degradation following ubiquitination at the C-
terminus by a network of negative regulatory proteins such as murine double minute 2 
(MDM2) and MDMX (encoded by the MDM4 gene) (Moll & Petrenko, 2003).  The E3 
ubiquitin-ligase MDM2 triggers proteosomal degradation while MDMX, which has no 
ubiquitin ligase function (due to a dysfunctional RING domain), forms heterodimers with 
MDM2, thereby enhancing its activity (Linares, Hengstermann, Ciechanover, Muller, & 
Scheffner, 2003).   As such, both MDM2 and MDM4 are considered oncogenes and 
their over-expression is seen in cancers such as sarcomas (20%) and breast cancer 
(15%).  Function and stability of p53 is also regulated by diverse post-translational 
modifications largely in response to stress signals: for example, phosphorylation by the 
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DNA damage-induced kinases ATM/ATR and checkpoint control kinases CHK1/CHK2 
upon genotoxic stress at the N-terminal domain (reversed by phosphatases like PPA2), 
acetylation at the negatively charged C-terminus and the DNA binding domain by the 
histone acetyl transferase P300/CBP and methylation of the C-terminus by the 
methyltransferases SET9 and/or PRMT5 (Figure 1).  Conversely, the NAD-dependent 
histone deacetylase SIRT1 attenuates p53 function by deacetylation (Figure 1).  It is 
important to consider that similar to epigenetic marks on histone tails, methylation, 
acetylation or ubiquitination can even affect the same lysine residue within p53, often 
leading to opposing biological effects.  
Thus, different strategies are needed for therapeutic approaches towards TP53 
mutant and TP53 wild-type cancers.  In murine models, reconfiguration of mutant p53 to 
its active WT function restores apoptosis and promotes retardation and even regression 
of advanced tumors (Martins, Brown-Swigart, & Evan, 2006; Ventura et al., 2007).  In 
the context of TP53 wild-type, we have shown in a PTEN-/- prostate cancer mouse 
model that disrupting STAT3 in the prostate epithelium leads to a defect in senescence 
control through the p14(ARF)/TP53 axis and aggressive tumor growth ensues.  Hence, 
senescence must be overcome for cancer development and aggressive tumor growth is 
promoted by pro-inflammatory JAK-STAT pathway activation (Pencik et al., 2016; 
Pencik et al., 2015). 
This review focuses on therapeutic methods to reactivate wild-type or mutant p53 
and their outcome in preclinical and clinical studies. 
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Figure 1: Schematic representation of the domain structures of p53, MDM2 and MDM4. A p53 
domain structure is shown with an N-terminal transactivation domain (TAD) a proline-rich domain (PR), a 
DNA binding core domain (DBD), an oligomerization domain (OD) allowing for TP53 tetramerization and 
a protein stability regulatory domain (RD) at the C-terminus. Following DNA damage CHK1, CHK2, ATM 
and ATX kinases phosphorylate p53 at multiple serine and threonine residues leading to p53 stabilization, 
whereas the phosphatase PP2A can reverses p53 phosphorylation.  The NAD-dependent deacetylase 
SIRT1 attenuates p53 function but p53 acetylation by P300/CBP activates it.  SET and PRMT5 are 
methyl-(M) transferases that act C-terminally on the oligomerization and regulatory domains of p53.  B 
MDM2 is an ubiquitin (Ub) ligase that acts on the C-terminus of p53.  MDM2 and MDM4 (also called 
MDMX) have a similar domain structure with a p53 binding domain at the N-terminus, an acidic domain, a 
zinc finger motif and finally the RING domain at the C-terminus, which is responsible for ubiquitination 
(the RING domain is not active in MDMX). 
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1. Targeting Mutant Forms of p53 
1.1 Small Molecules Targeting Mutant p53 
Small molecules have been developed that specifically target mutant forms of 
p53 restoring p53 transcriptional activity, thereby leading to cell cycle arrest or 
apoptosis of tumor cells (for overview see Table 1,2).  According to the International 
Agency for Research on Cancer’s (IARC) TP53 mutation database (April 2016), the 
three most often mutated residues of p53 in cancer are the arginines in positions 175, 
248, and 273 (Figure 2), (Bouaoun et al., 2016).  In 2002, the low molecular weight 
compound PRIMA-1 was identified from a National Cancer Institute (NCI) substance 
library screen (Bykov et al., 2002).  A further compound identified by the same group, 
MIRA-1 was not further followed up due to toxicity issues (Bou-Hanna et al., 2015; 
Bykov et al., 2005).  The selection criteria used by the Bykov group to identify these 
compounds was the ability to preferentially kill mutant p53 as opposed to TP53 deleted 
cell lines by restoring transcriptional activity of mutant or unfolded p53 (Bykov et al., 
2002). 
                             
Figure 2: p53 mutations that disrupt DNA binding or destabilize protein folding and substances 
that can rescue these mutations. Mutations at sites 248 and 273 are the most frequently detected in 
cancer and are involved in direct binding to DNA.  Small molecules that restore DNA binding (collectively 
denoted by X in the diagram) are not mutation site-specific and include PRIMA, APR-246, CP31398, 
Ellipticine analogs and JNJ26854165.  In contrast the arginine175 mutation is important for zinc binding to 
p53, which is required for correct folding.  This mutation can be rescued by the novel drug zinc 
metallochaperone 1 (ZMC-1).  The Y220C mutation is not involved in DNA binding, but destabilizes p53’s 
3-D structure by forming a crevice that can be targeted by PhiKan-type small molecules.  
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PRIMA-1 and its derivative PRIMA-1MET, now called APR-246, can restore a WT 
conformation to mutant p53 and in doing so reinstate transcriptional activity leading to 
expression of Puma, Noxa and Bax in p53 mutant cells (Shen, Vakifahmetoglu, Stridh, 
Zhivotovsky, & Wiman, 2008; T. Wang, Lee, Rehman, & Daoud, 2007).  Both 
compounds are converted intracellularly to Michael acceptor methylene quinuclidinone 
(MQ) that binds covalently to cysteines in mutant p53.  Moreover, transfer of MQ-
modified mutant p53 into p53 null tumors induces expression of p53 downstream target 
genes indicating that covalent binding alone of MQ is sufficient (Lambert et al., 2009).   
In vivo, PRIMA-1 has shown impressive activity in murine xenograft models of 
osteosarcoma (Bykov et al., 2002).  Further cytotoxic and apoptotic effects of the 
derivative APR-246 have been observed in diverse murine cancer models such as 
mutant p53 small cell lung carcinoma (Zandi et al., 2011), multiple myeloma (Saha, 
Jiang, Yang, Reece, & Chang, 2013), melanoma (Bao et al., 2011) and breast cancer 
(Liang, Besch-Williford, & Hyder, 2009).  In 2012, APR-246 was tested in a phase I/IIa 
clinical trial of 22 patients with hematologic malignancies or prostate cancer (TP53 
mutation status was not a pre-selection criterion). The drug was generally well tolerated 
with only transient side effects such as fatigue, dizziness, headache, and confusion.  
Two minor responses were observed in this late stage cohort, one in an acute myeloid 
leukemia (AML) patient carrying V173M mutant p53, the other one in a non-Hodgkin 
lymphoma patient with a TP53 splice site mutation (Lehmann et al., 2012).  Currently, 
APR-246 is under study in a phase Ib/II clinical trial of high grade serous ovarian cancer 
in combination with pegylated doxorubicin and carboplatin (NCT02098343; 
www.clinicaltrials.gov).   
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The activity of APR-246 is not limited to p53 in that it is also able to restore 
function of the analogous p63 mutant, thereby reversing the differentiation block caused 
by this mutant protein and extending the use of this exciting compound to mutant p53 
analogs (Rokaeus et al., 2010).  TP53 shares high sequence homology with TP63 in its 
DNA binding domains.  Deactivation of p63 as a consequence of point mutations in the 
encoding gene leads to severe developmental defects including ectodermal dysplasia, 
limb defects, and orofacial clefting (EEC syndrome).  APR-246 rescues epidermal 
differentiation in skin keratinocytes derived from patients with EEC syndrome (Shalom-
Feuerstein et al., 2013; Shen et al., 2013).  
Y220C p53 is one of the less frequently observed mutations, although it is 
estimated that 75,000 new cancer cases per year bear this mutation, which is 
comparable to the number of patients carrying the BCR-ABL translocation.  This 
mutation, in the core domain of p53 is not involved in DNA binding, but the Y220C 
substitution creates a cavity that destabilizes p53.  The small molecules PhiKan083 and 
PhiKan7088 bind to this cavity and therefore interact with Y220C p53.  They were 
designed by molecular modeling based on the X-ray crystal structure of this mutant.  In 
vitro, PhiKan7088 permits the correct folding of Y220C p53 restoring transactivation 
potential and hence inducing expression of p21 and Noxa, leading to cell cycle arrest 
and apoptosis (Figure 2) (Boeckler et al., 2008; X. Liu et al., 2013).  Altogether, small 
molecular weight compounds constitute a promising approach for targeting specific 
mutant p53 forms and their further development addresses a great clinical need. 
The quinazoline derivative CP-31398 was selected from a screen of over 
100,000 compounds looking for those that could restore wild-type conformation of DNA 
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binding domain (DBD) mutants of p53, using the conformation-specific antibody 
PAb1620 as a probe (Foster, Coffey, Morin, & Rastinejad, 1999).  The exact 
mechanism of action of CP-31398 is unclear, since NMR studies have not been able to 
show direct binding of CP-31398 to p53 (Rippin et al., 2002).  In vivo studies of a 
transgenic APCmin colon cancer mouse model demonstrated that CP-31398 suppresses 
APCmin induced colon cancer development; CP-31398 treatment induced apoptosis of 
tumor cells with elevated levels of p53 and expression of p21 detected (Rao, Swamy, 
Patlolla, & Kopelovich, 2008).  Furthermore, in a mouse model of UVB-induced skin 
carcinogenesis, a reduction in tumor growth was observed (Tang et al., 2007).  More 
recently, when applied to pancreatic adenocarcinoma cell lines, CP-31398 induced 
apoptosis as well as autophagy, although active concentrations were above 10µM 
(Fiorini et al., 2013).  New analogs have now been developed that lack the unstable 
styryl linkage in the side chain of CP-31398 and are showing promising first results 
(Sutherland et al., 2012).  Another small molecule that specifically binds the p53 DBD is 
SCH529074; this interaction restores wild-type function and concomitantly inhibits 
ubiquitination of p53 by HDM2 (Demma et al., 2010). 
Ellipticine analogs have also been tested for p53-dependent cytotoxic activity 
within the anticancer drug discovery program of the US National Cancer Institute (NCI) 
(Shi et al., 1998).  Ellipticine restores transactivation inducing expression of p21 and 
MDM2 in several p53 mutant-expressing cell lines as well as in nude mouse tumor 
xenografts (Peng, Li, Chen, Sebti, & Chen, 2003).  Ellipticine was shown to sensitize 
p53 mutant cells to doxorubicin-induced apoptosis in human lymphoma cell lines (F. 
Wang et al., 2011).  However, other mechanisms such as DNA intercalation, 
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topoisomerase II inhibition and formation of DNA adducts may also be involved 
(Poljakova et al., 2009).   
Similar to PRIMA discussed above, RITA (reactivation of tumor cell apoptosis) 
was also derived from the NCI library.  RITA is able to kills p53 WT HCT116 colon 
cancer cells more effectively than the isogenic p53 mutant version of this cell line and 
also shows activity in murine xenograft models (Issaeva et al., 2004; J. Yang et al., 
2009).  RITA targets the N-terminus of p53 and through conformational change 
prevents the binding of negative regulators such as MDM2 or HPV E6 (Enge et al., 
2009; C. Y. Zhao, Szekely, Bao, & Selivanova, 2010).  More recently, Selivanova and 
colleagues showed in neuroblastoma that RITA’s mechanism of action can be extended 
to both mutant (C135F, M246R) and WT p53. When activated by RITA, p53 inhibited 
key oncogenes including n-Myc, BCL2, MDM2 and MDMX (Burmakin, Shi, Hedstrom, 
Kogner, & Selivanova, 2013).  Recently, a study suggested that RITA-resistant cell lines 
show increased DNA cross-link repair and are therefore also resistant to crosslinking 
agents like cisplatin, indicating that the mechanism of action may be inducing DNA 
damage upstream of p53 rather than a direct effect on p53 (Wanzel et al., 2016). 
 
1.2 Restoration of Mutant p53 with Zinc 
p53 contains a single zinc ion close to its DNA binding interface.  Zn2+ is 
essential for site-specific DNA binding, activation of downstream targets and correct 
protein folding.  Loss of metallothioneins, which store intracellular zinc, promotes the 
unfolding of WT p53 and inhibits its transcriptional activity (Puca et al., 2009).  If p53 
bears the R175H mutation its capacity for zinc binding is abrogated.  
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Screening of a small compound library has shown that the small molecule zinc 
metallochaperone-1 (ZMC1) was able to restore WT function specifically to this mutant 
form of p53. The reason for this may be that ZMC1 is a zinc ion chelator, which enables 
transport of the ion through the cell membrane (Blanden et al., 2015; X. Yu et al., 2014). 
ZMC1 may pave the way for future clinical molecules that restore function to the 
common R175H p53 mutant.  Another compound NSC319726 seems also to be a zinc-
chelator and restores function of the R175H p53 mutant in both cancer cell lines and 
tumor xenografts (X. Yu, Vazquez, Levine, & Carpizo, 2012). 
 
1.3 Proteosomal Depletion of Mutant p53 
Rationale for this strategy includes selective degradation of dominant negative 
mutant forms of p53 or the depletion of mutant forms that have GOF properties.  For 
this approach, compounds were screened for degradation of mutant p53 but not WT 
p53.  Mutant p53 is stabilized by interaction with the heat shock protein Hsp 70 and Hsp 
90 chaperone complex that depends on HDAC6 interaction for activation (Li, 
Marchenko, Schulz, et al., 2011).  Several Hsp 90 inhibitors have been developed and 
include geldanamycin, 17-AAG and ganetespib.  In murine models, ganetespib showed 
a 50-fold higher potency than 17-AAG in destabilizing mutant p53 (Alexandrova et al., 
2015).  Ganetespib was tested in a phase II trial for Non-Small Cell Lung Cancer 
(NSCLC) together with docectaxel and showed increased progression-free survival 
although a phase 3 study that closed this year (NCT01798485) could not reproduce 
these findings (Ramalingam et al., 2015).  
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Similar approaches include, histone deacetylase inhibitors (HDAC) such as 
suberoylanilide hydroxamic acid (SAHA), also called Vorinostat or Zolinza.  Vorinostat 
can destabilize the complex formed between Hsp90 and mutant p53 and shows 
preferential cytotoxicity in mutant p53 cancer cells (Li, Marchenko, & Moll, 2011).  
Vorinostat was approved by the FDA in 2006 for the treatment of cutaneous T cell 
lymphoma and is being trialed in other cancers including myelodysplastic syndrome and 
Sézary syndrome (L. Ding et al., 2015). 
Arsenic trioxide (ATO) is used in combination with all trans retinoic acid (ATRA) 
as a curative therapy for acute promyelocytic leukemia (APL).  Like ATRA it also leads 
to the degradation of the PML-RARα fusion protein thereby allowing terminal cell 
differentiation (Lallemand-Breitenbach & de The, 2013).  We have shown that p53 
mutant cells of chronic lymphocytic leukemia patients are selectively killed by ATO 
(Merkel et al., 2008).  This may at least in part be explained by data from Yan and 
colleagues who showed that ATO can reactivate proteasome-dependent degradation of 
mutant p53 in cancer cells partly through enhanced expression of the Pirh2 E3 ligase 
(Yan, Jung, Zhang, & Chen, 2014).  
Disulfiram (DSF) has ubiquitin proteasome-targeting activity inhibiting 
acetaldehyde dehydrogenase and as such is in use for the treatment of chronic 
alcoholism.  Interestingly, DSF was shown to act synergistically with doxorubicin in the 
mutant p53 breast cancer cell line MDA-MB-231(Robinson et al., 2013).  Recently it has 
been evaluated as an adjunct to chemotherapy in metastatic NSCLC with remarkable 
success (Nechushtan et al., 2015).  Gambogic acid is derived from the Garcinia 
hanburyi tree and induces proteasomal degradation of mutant p53 (J. Wang et al., 
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2011).  Spautin-1, an inhibitor of autophagy also has an unexpected role in mutant p53 
degradation.  When cancer cells are challenged by starvation, cells start a process of 
macro-autophagy during which intracellular proteins and organelles are degraded 
through lysosomes, providing an alternative energy source.  Spautin-1 controls levels of 
p53 by regulating the deubiquitinating activity of USP 10 and USP 13 (J. Liu et al., 
2011).  Under a glucose-free environment with confluent growth conditions, spautin-1 
inhibits macro-autophagy and induces degradation of several mutant p53 forms by a 
specific form of autophagy, namely chaperone-mediated autophagy (Vakifahmetoglu-
Norberg et al., 2013).  This is an interesting new concept that may lead to novel forms 
of therapy for p53 mutant solid cancers and the recent Nobel prize in medicine awarded 
for the discovery of autophagy might raise research interest in this underexplored area. 
 
1.4 Targeting proteins that modulate p53 function 
An alternative approach towards targeting mutant p53 activity is either to 
reactivate tumor suppressive pathways inhibited, or to suppress oncogenic targets 
activated by it.  As seen before, mutant p53 can exert GOF activity by binding and 
thereby inhibiting the tumor suppressor functions of p63 and p73.  Accordingly, the 
disruption of mutant p53 in complex with p63 and p73 appears an alternative to the 
refolding approach of mutant p53.  For example, the small molecule RETRA suppresses 
mutant p53-bearing cancer cells through inhibition of the mutant p53/p73 complex and 
induction of p73 expression (Kravchenko et al., 2008). 
The R280K or R273H DBD mutants of p53 when engineered into mice, disrupt 
mammary tissue architecture by inducing the mevalonate/cholesterol synthesis pathway 
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(Freed-Pastor et al., 2012).  Statins inhibit the rate limiting enzyme in this pathway 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and are widely used for 
the treatment of hypercholesterinemia and prevention of cardiovascular disease.  
Hence, statins restore morphology and decrease survival of mutant p53 breast cancer 
cell lines (Freed-Pastor et al., 2012).  Statins also block phosphorylation of oncogenic 
MYC, which together with their impact on cholesterol metabolism and membrane 
integrity could help to explain their broader anti-cancer action. 
Modification of p53 is also conducted by proteins typically associated with 
epigenetic histone marks such as those that mediate lysine methylation and acetylation.  
For example, the methyltransferases SMYD and SET7 methylate lysines in the C-
terminus of WT p53 in teratocarcinoma cell lines compromising its transcriptional 
activity. Thus, inhibition of these proteins leads to p53 reactivation and differentiation of 
the teratocarcinoma cells suggestive of a possible therapeutic avenue (Zhu, Dou, 
Sammons, Levine, & Berger, 2016).  In a similar vein, mutant GOF p53 has been shown 
to bind to the transcription factor ETS2 thereby activating transcription of the 
methyltransferases MLL1 and MLL2 as well as the acetyl transferase MOZ1. MLL family 
members are core components of large protein complexes that modify chromatin 
structure and hence gene transcription and in the case of p53 GOF mutants, induce 
transcription of genes associated with tumor cell proliferation. Thus, highly specific 
inhibitors of MLL complex formation in p53 GOF mutant cells block cell proliferation but 
do not affect p53 WT cells (Zhu et al., 2015). 
 
2. Reactivation of WT p53 
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2.1 MDM2 and/or MDMX Inhibitors  
In numerous tumors, TP53 is not mutated but inactivated due to (over)expression 
of negative regulatory proteins such as MDM2 and MDMX.  Deregulation of the 
autoregulatory feedback loop between p53 and MDM2 proteins neutralizes p53 tumor 
suppressor function.  Therefore, disruption of p53/MDM2/MDMX interactions by small 
molecules may reactivate the p53 pathway in tumor cells retaining WT p53.  The MDM2 
protein was isolated in 1987 as the protein product of extrachromosomal circular DNA 
amplifications, also called ‘double minutes’, in transformed 3T3 cell lines (Cahilly-
Snyder, Yang-Feng, Francke, & George, 1987).  MDM2 regulates p53 by two main 
mechanisms: inducing p53 degradation (by acting as an E3-ubiquitin ligase) and directly 
suppressing the transactivation domain of p53, hence preventing transcription of 
downstream targets.  In contrast, MDMX has no ubiquitin ligase function, but shares 
MDM2s ability to inhibit transcription of p53 downstream targets.  A prerequisite for the 
ubiquitin ligase function of MDM2 is the formation of homo-oligomers, which depends 
on the carboxy-terminal RING domain; MDMX does not form homo-oligomers.  
However, hetero-oligomerization between MDMX and MDM2 is needed for optimal 
ubiquitin-ligation through MDM2 (Francoz et al., 2006; Momand, Zambetti, Olson, 
George, & Levine, 1992; Wu, Bayle, Olson, & Levine, 1993).  The p53/MDM2 
interaction brings together the N-terminus of the p53 transactivation domain with the 
first 120 amino acids of the MDM2 N-terminus.  The X-ray crystal structure of MDM2 
bound to a p53 peptide revealed Phe19, Trp23 and Leu26 as the key residues creating 
a locally restricted, hydrophobic interaction site within p53 (see Figure 3) (Kussie et al., 
1996).  Accordingly, peptides with the same or similar sequence were screened for their 
DRUG DISCOVERY TARGETING THE P53 PATHWAY 17 
 
ability to interfere with MDM/p53 binding.  Peptides are polar, large molecular weight 
compounds; structural mimetics and screens of compounds blocking MDM2 binding are 
an area of future investigation.  
 
2.1.1 MDM2 inhibitors: peptides. 
One mechanism to inhibit MDM2 activity is to design peptide-mimics of p53 that 
block, via steric hindrance the p53 binding site of MDM2.  WT p53 peptide 
encompassing the helical MDM2 binding site has comparatively low binding affinity for 
MDM2.  To improve affinity, the amino acid sequence of p53 peptides has been 
optimized using phage display techniques and in silico structure-guided approaches.  
Introduction of non-natural amino acids that allow for additional interpeptidic bonds have 
been introduced into the peptide sequence, a method also called “stapling”.  This has 
led to enhanced affinity by reducing conformational flexibility, increasing the half live of 
the peptides and enabling cellular uptake.  One of the first inhibitors of this type is SAH-
p53-8, a stapled p53 peptide made cell permeable by the introduction of positively 
charged amino-acids.  In contrast to an inactive mutant form, SAH-p53-8F19A, SAH-
p53-8 can reactivate p53, induce p21 and lead to apoptosis of the SJSA-1 
osteosarcoma cell line.  However, concentrations (10-15 µM) needed to exert these 
effects are relatively high (Bernal, Tyler, Korsmeyer, Walensky, & Verdine, 2007).  
Another peptide that binds MDM2 is sMTide-02A detected using phage-display 
techniques and modified (through stapling, removal of proline 12 and a change of 
asparagine 8 to alanine) to bind to the p53-binding pocket of MDM2 with high affinity (it 
has a remarkably low Kd value of 6.76 nM) (Pazgier et al., 2009; Phan et al., 2010).  
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This peptide leads to G1 and G2 arrest in different p53 wild-type cell lines without 
induction of apoptosis (Brown et al., 2013).  
 
2.1.2 MDM2 inhibitors: small molecules. 
The small size of the MDM2/p53 interface has made it possible to design not only 
peptides but also small organic compounds that block this interaction (Figure 3).  
Compound screens, structure-guided in silico searches or de novo design, have 
identified molecules that are able to disrupt this interaction by binding the MDM2/p53 
interface of MDM2.  The most promising MDM2/p53 disruptors belong to different 
classes of compounds: nutlins, spirooxindoles and piperidinones.  Nutlin-3a was 
developed in 2004 by Hoffmann la Roche with the group of Vassilev et al. (Vassilev et 
al., 2004) and inhibits the association of MDM2 with p53 via binding to the hydrophobic 
cleft of MDM2 (Figure 2 B).  Nutlin-3a is a potent MDM2 inhibitor and shows efficacy in 
primary chronic lymphocytic leukemia cells that are wild-type for p53 (Coll-Mulet et al., 
2006; Kojima et al., 2006; Secchiero et al., 2006) and in many tumor cell lines from 
various malignancies including acute myeloid leukemia (Kojima et al., 2005), 
chemoresistant neuroblastoma (Van Maerken et al., 2009), anaplastic large cell 
lymphoma (Y. Cui et al., 2009; Y. X. Cui et al., 2009) or more recently multiple myeloma 
(Surget et al., 2012).  However, due to poor bioavailability and high toxicity its use in the 
clinic has been hampered.  The nutlin analog RG7112 was first clinically evaluated in 
MDM2-amplified liposarcoma patients showing that it could indeed amplify the p53 
pathway in patients (Ray-Coquard et al., 2012).  In addition, a phase I clinical trial of 
patients with relapsed refractory leukemia was performed recently (Andreeff et al., 
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2016).  Toxicities include gastrointestinal and hematologic side-effects (neutropenia, 
thrombocytopenia).  Among the AML patients, five out of 30 patients reached complete 
or partial responses and 9 patients entered stable disease.  Furthermore, two patients 
with mutant p53 (R181L and G266E) showed a clinical response.  The latest addition to 
this group of compounds is RG-7388 which shows greater effects in the induction of p53 
in the osteosarcoma cell line SJSA-1 and accordingly is also able to reduce growth of 
engrafted SJSA-1 cells in mice at lower concentrations than RG-7112 and Nutlin-3a (Q. 
Ding et al., 2013).  Currently, a number of phase I clinical trials with MDM2 inhibitors in 
combination with other agents are being evaluated for example a phase Ib study in AML 
patients with cytarabine (Martinelli et al., 2013) or in combination with trabectedin in 
sarcomas (Obrador-Hevia et al., 2015).   
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Figure 3: Drugs that interact with the MDM2/p53 binding pocket.  The mechanism of most MDM2 
inhibitors is binding into the hydrophobic p53-binding cleft of MDM2.  Critical for MDM2 binding are the 
hydrophobic p53 amino acids phenylalanine 19 (F19), tryptophan 23 (W23) and leucine 26 (L26).  Drug 
classes used to displace p53 are peptides (P), Nutlins (N), Spirooxindoles (S) and Piperidinones (Pi).  
 
Another interesting class of MDM2 inhibitors is the spirooxindole family, initially 
developed by the Wang group at the University of Michigan (Y. Zhao et al., 2013).  This 
family of compounds was identified by structure-guided de novo design in an effort to 
mimic within an organic molecule the three key hydrophobic residues in the MDM2 
binding pocket of p53: Phe19, Trp23 and Leu26.  This study resulted in the 
development of a series of ‘MI’ compounds, key amongst which is MI-63 which binds 
MDM2 with a Ki of 3 nM and in turn activates p53, inhibiting cell growth in p53 wild-type 
cells (K. Ding et al., 2006).  Further investigations led to the development MI-147 
showing p53 modulating activity in SJSA-1 osteosarcoma and HCT116 colon carcinoma 
cell lines (S. Yu et al., 2009).  In SJSA-1 osteosarcoma xenografts, MI-147 alone and in 
combination with irinotecan showed strong potency and continues to undergo preclinical 
evaluation.  Another member to this class of compounds is MI-888, which through 
changes in the stereochemistry reduces the Ki value to 0.44 nM and has also been 
shown to have activity in murine xenograft models upon oral administration (Y. Zhao et 
al., 2013).  Finally, SAR405838, a highly potent and selective MDM2 inhibitor was 
identified and shown to halt tumor growth or lead to durable remissions in murine 
engraftment models of osteosarcoma, acute leukemia, prostate cancer and colon 
cancer (S. Wang et al., 2014).  In dedifferentiated liposarcoma, a disease which is 
characterized by high MDM2 expression and usually wild type p53, SAR405838 gave 
rise to p53 activation and tumor regression at much lower concentrations than 
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comparable substances such a Nutlin3a and MI-219 (Bill et al., 2016).  However, a 
recent publication has shown development of p53 mutations during SAR405838 
treatment in patients with dedifferentiated liposarcoma, suggesting fast acquisition of 
resistance (Jung et al., 2016).  
Another class of MDM2 inhibitors are piperidinones, such as AMG232 that 
inhibits tumor growth in SJSA-1 osteosarcoma xenografted mice (Canon et al., 2015; 
Sun et al., 2014).  Currently, AMG232 is under investigation in a phase I study of 
patients with solid tumors or multiple myeloma (NCT01723020), in a phase Ib study with 
or without co-administration of the MEK1/MEK2 inhibitor trametinibin in AML 
(NCT02016729) and in a phase Ib/IIa in combination with trametinib and dabrafenib in 
patients with metastatic melanoma (NCT02110355).  
 
 2.1.3 MDMX inhibitors. 
 Resistance to MDM2 antagonists can develop as a consequence of amplification 
of MDM4 preventing transactivation of p53 target genes (Graves et al., 2012; Wade, 
Rodewald, Espinosa, & Wahl, 2008; Wade, Wong, Tang, Stommel, & Wahl, 2006).  
Therefore, in such cases parallel inactivation of MDMX may be of benefit.  Whilst most 
MDM2 inhibitors also bind MDMX they do so with a lower Kd that is not sufficient for 
total deactivation.  For example, in vitro binding studies have shown that Nutlin-3a binds 
MDM2 with 500-fold selectivity over MDMX.  Hence, there is a need to develop specific 
MDMX inhibitors.  One of the first of this class of compounds is SJ-172550, which binds 
reversibly to MDMX inhibiting the p53 binding domain and inducing apoptosis in 
retinoblastoma cells known to express high levels of MDMX (Reed et al., 2010).  
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However, the stability of covalent adducts formed between SJ-172550 and thiol groups 
within the MDMX p53-binding pocket is dependent on variable factors, which 
complicates its use as a therapeutic agent (Nikulenkov et al., 2012). A second 
compound is XI-006, which acts through suppression of MDMX transcription as 
assessed by a MDMX promoter-linked luciferase assay (H. Wang, Ma, Ren, 
Buolamwini, & Yan, 2011) whereas RO-5963 leads to forced dimerization of MDMX 
through interaction with its RING-domain, inhibiting its ability to form complexes with 
p53 and as a consequence was shown to overcome Nutlin-3a resistance when due to 
high expression of MDMX (Graves et al., 2012).  A scheme of the mode of action of the 
MDMX inhibitors described is given in Figure 4.  
 
Figure 4: MDMX inhibitors and their mechanism of action.  SJ172550 is a compound that binds to the  
p53 binding pocket of MDMX via disulfide bonds. RO-5963 acts by dimerization of MDMX through binding 
to the RING domain.  
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Another lead in the design of dual MDM inhibitors is lithocholic acid, a steroid 
fatty acid also naturally present in bile acid, which was found to preferentially target 
MDMX over MDM2, raising the possibility that certain steroids may be natural ligands of 
MDM proteins.  However, low solubility and apoptosis inducing activity only at 
concentrations above 100 µM prevent its use as a therapeutic drug (Vogel et al., 2012).  
Lipid side chain modifications of lithocholic acid and cytochrome P450 action might 
overcome these limitations in future approaches. 
 
2.2 Targeting p53 Upstream Regulators 
 As previously mentioned, p53 stability and activity is regulated by post-
translational modifications and therefore modulation of these events also presents 
therapeutic options. Persistent acetylation of p53 promotes protein stabilization and also 
activation of downstream targets. Tenovin-6, a small molecular weight sirtuin 
deacetylase SirT1 enzyme inhibitor blocks p53 deacetylation. Hence Tenovin-6 induces 
apoptosis of acute lymphoblastic leukemia cells and their stem cells, as well as uveal 
melanoma cells with mutant p53 (Dai, Zhou, Jin, & Pan, 2016; Jin et al., 2015). When 
DNA damage induces cell cycle arrest it is no surprise that p53 mutant cells are highly 
dependent on the G2/M checkpoint, since they are unable to initiate G1 arrest via p21 
and CDK2. Therefore it is an interesting “synthetic lethal” strategy to enforce lethal 
G2/M transition, by keeping the checkpoint kinase CDK1 in its active dephosphorylated 
state (Bauman & Chung, 2014). This can be achieved by inhibiting the kinases Wee1 
(MK-1775) or Chk1 (AZD7762) that usually mediate G2/M arrest by ensuring CDK1 
phosphorylation.  Accordingly, in a p53 mutant head and neck squamous cell carcinoma 
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(HNSCC) engraftment model, the Wee1 kinase inhibitor MK-1775 displays single-agent 
activity and potentiates the efficacy of cisplatin (Moser et al., 2014). 
 
3. Vaccination and Gene Therapy Approaches 
3.1 TP53 Vaccination 
 Tumor vaccination is an exciting concept in the era of immunotherapy and 
tumor neoantigen vaccination strategies yet cancer vaccination programs have gone 
through phases of enthusiasm and disappointment.  Recently, further development and 
a better understanding of the immune system have led to improved novel strategies.  
Early phase clinical trials using peptides that activate dendritic cells or vector-based 
strategies have had very limited clinical effect, suggesting effective immune evasion by 
tumors (Goldman & DeFrancesco, 2009).  Immunomodulatory escape mechanisms 
include changes in CD4+FoxP3+ regulatory T cells (Tregs) suppressing the adaptive 
immune response, expression of the co-stimulatory protein CTLA-4, which induces T-
cell anergy and/or differential regulation of programmed death ligand 1 (PD-L1) and its 
receptor PD-1 restraining the tumor killing effect of T-cells (Chen & Han, 2015; Ma, 
Gilligan, Yuan, & Li, 2016; Ohaegbulam, Assal, Lazar-Molnar, Yao, & Zang, 2015). 
 Ideally, the tumor-associated antigen used for vaccination should have three 
properties: First, it should be exclusively expressed on tumor tissues, second, be 
essential for tumor growth and third, possess immunogenic properties.  Unfortunately, 
p53 is expressed in both healthy and tumor cells.  Nevertheless, it has been shown that 
CD8 T cells directed against wild-type p53 can discriminate between p53-presenting 
tumor cells and normal tissue (Nijman, Lambeck, van der Burg, van der Zee, & 
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Daemen, 2005).  The reasons for this remain unclear and may be related to the higher 
levels of p53 expressed in cancers, particular mutant forms of p53 leading to elevated 
levels of processing and presentation on immune cells.  Indeed, higher levels of p53 
antibodies have been found in patients with lung, pancreatic, bladder and breast cancer 
and in patients expressing mutant forms of p53, although the levels of antibody 
production are obviously insufficient to eradicate the tumors (Angelopoulou, Diamandis, 
Sutherland, Kellen, & Bunting, 1994; Met, Balslev, Flyger, & Svane, 2011).  In a study of 
21 ovarian cancer patients, p53 peptide-pulsed dendritic cells (p53 amino acids 264-
272) were compared to subcutaneous injection of the same p53 peptide together with 
the myeloid cytokine GM-CSF.  An immune response was detected in 83% and 69% of 
the patients as tested by ELISPOT-assays in the two arms respectively, suggesting 
successful immunization in both arms. Administration of IL-2 in both arms generated 
grade 3-4 toxicities and boosted the presence of Tregs precluding its clinical 
applicability.  Both arms of the study had similar progression-free and overall survival, 
with minor toxicities, suggesting subcutaneous injection to be as effective as peptide-
pulsed approaches (Rahma et al., 2012).  More recently, the results of a phase Ib trial 
dendritic cell p53 peptide vaccine for head and neck cancer were published (P. J. 
Schuler et al., 2014).  Adjuvant p53 vaccination of 16 patients was safe with a two-year 
disease-free survival of 88%. In 69% of the patients, p53-specific T cells increased post-
vaccination confirming the rational for the study. 
 
3.2 Gene Therapy Strategies 
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 TP53 gene therapy is based on delivery of a wild-type TP53 gene into tumor 
cells.  The first human study was reported in 1996 by Roth et al., in which a retrovirus 
carrying human TP53 was directly injected into NSCLC (Roth et al., 1996).  However, 
use of retrovirus remains a threat due to the potential for oncogene activation as a result 
of retroviral insertion into the host genome (Bishop, 1982).  Hence, alternatives that 
minimize this problem have been explored including adenoviral vector gene delivery.  
One such vector is Gendicine, a recombinant adenoviral human TP53 vector that 
received approval in China in 2003 for use in combination with radiotherapy for the 
treatment of head and neck cancer.  Gendicine has also been investigated for its 
efficacy when administered in combination with fractionated stereotactic radiotherapy 
for the treatment of hepatocellular carcinoma and showed improved one-year survival 
rates (Z. X. Yang et al., 2010).  In the USA, adenoviral p53 vectors such as SCH-58500 
(CANJI, Inc.) and Advexin (Introgen Therapeutics) have been investigated in various 
clinical trials (M. Schuler et al., 2001; Shimada et al., 2006).  However, companies 
pursuing this avenue have since closed down like Advexin, or been bought by Merck 
like CANJI, Inc. and no active clinical trials can currently be found on databases 
suggesting severe problems associated with this strategy.   
 
3.3 TP53 Oncolytic Viruses 
 Because of the low transduction efficiencies of TP53 via adenoviral-based 
vectors, other strategies have been developed.  This approach uses replicating viruses 
for selective killing of tumor cells and is based on the long-known observation that 
tumors regress following viral infection, which may be caused by interferon and or 
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acquired immune responses (Bluming & Ziegler, 1971; Hansen & Libnoch, 1978).  An 
example of TP53-based oncolytic virotherapy is dl-1520 (Onyx-015) in which the viral 
E1B-55KDa gene has been deleted.  E1B proteins interact with p53, inducing its 
degradation, therefore enabling host cell survival and subsequent viral replication.  
Hence, in TP53-deficient tumors, virus lacking the E1B proteins are able to replicate, 
whereas in normal cells p53 is activated preventing cellular survival and as a corollary 
viral replication.  As such Onyx-015 presents a relatively specific therapy whereby virus 
replication only occurs in tumor cells that lack p53 resulting in cytolysis (Bischoff et al., 
1996).  Onyx-015 was investigated in numerous phase I/II clinical trials of malignant 
gliomas, hepatobiliary tumors and sarcomas (Chiocca et al., 2004; Galanis et al., 2005; 
Makower et al., 2003).  However, the clinical response to Onyx-015 was mixed, it 
reached phase III in combination with chemotherapy for head and neck cancer, but the 
trial was not completed and Onyx-015 did not obtain FDA approval.  For different 
reasons, further clinical development was not pursued.  A further oncolytic virus, H101 
was developed and licensed for cancer therapy in China.  H101 lacks the viral E1B 
genes in addition to E3 which encodes the adenovirus death protein (W. Yu & Fang, 
2007).  In phase II/III trials for treatment of head and neck carcinomas, it showed 
synergistic antitumor effects in combination with chemotherapy.  Two further oncolytic 
viruses are currently under investigation: H103, which has completed phase I trials and 
H102 which is still in the preclinical phase (Farnebo, Bykov, & Wiman, 2010; Guan, He, 
& Zou, 2016). 
 
3.4 MicroRNA based strategies 
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 MicroRNAs (miRNA) are small noncoding RNAs with a typical length of around 
20 nucleotides.  miRNAs usually bind to the 3‘-untranslated region of their target 
mRNAs and can either lead to degradation of the target mRNA or block translational 
protein synthesis.  Most miRNAs regulate multiple target genes and play an important 
role in physiological and pathological processes including cancer (Bartel, 2009).  Recent 
investigations have highlighted the contribution of miRNA in p53 regulation.  A group of 
miRNAs including miR-25, miR-30d and miR-125b have been shown to directly 
downregulate p53 expression whereas others including miR-192, miR-194, miR-215 
and miR-605 indirectly stabilize p53 through suppressing MDM2 (Deng & Sui, 2013; 
Pichiorri et al., 2010).  Of note, miRNA-34a, initially described as a p53 downstream 
target, can upregulate p53 activity through inhibition of multiple p53 negative regulators 
like SIRT1 (Hunten, Siemens, Kaller, & Hermeking, 2013).  miRNA-34a is an important 
tumor suppressor and its expression is silenced by epigenetic alteration in various 
cancers including esophageal, gastric, hepatocellular and colorectal cancers 
(Hermeking, 2010).  Two approaches for miRNA-34a restoration are currently under 
investigation:  Firstly, the use of epigenetic drugs which inhibit DNA methylation and 
histone deacetylation and thereby restore silenced miRNA-34a expression such as a 
combination of 5-Aza CDR and Vorinostat in the setting of pancreatic cancer (Nalls, 
Tang, Rodova, Srivastava, & Shankar, 2011).  Secondly, systemic delivery of miRNA-
34a mimics such as MRX34 developed by Mirna Therapeutics which is currently in 
phase I clinical trial as a monotherapy. Using this approach, partial responses have 
been reported in hepatocellular carcinoma, renal cell carcinoma and acral melanoma 
patients although, in three patients serious adverse events that were possibly immune-
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related were reported at the ASCO 2016 meeting (Beg Shaalan, 2016).  Therapeutic 
approaches employing miRNA are still hampered by issues of poor cellular uptake and 
will need careful monitoring for potential side effects due to their multiple targets. 
 
4. Outlook 
 To guard the integrity of a genome one has to restore the normal function of the 
“guardian of the genome”, namely p53. There are a plethora of direct or indirect 
targeting approaches that all have promising and important clinical implications: from 
those aiming either directly at, or upstream of p53, e.g. MDM2/MDMX, to 
immunotherapy and vaccination strategies, to miRNA targeting. In the clinical setting it 
will be important to tailor the strategy to the specific tumor type and its molecular status 
concerning p53, MDM and other biomarkers that may eventually be unraveled.  
 To date, small molecule inhibitors are those holding the greatest promise. Their 
size, polarity, solubility, pharmacokinetic and pharmacodynamic properties can be 
improved through sophisticated medical chemistry approaches. Furthermore, structural 
modeling and drug-target protein interaction studies have revealed a detailed, atomic-
level understanding of vulnerable nodes of p53 or MDM family members and how key 
protein interphases or pockets can be targeted. p53 cancer research activity in the 
future will include advanced structure-guided modeling combined with biological read-
out systems. Also, in vivo targeting in advanced p53 animal model systems and related 
early phase clinical trials will bring new momentum. Studies of inhibitors of MDM2 are, 
good examples of how basic research into regulatory factors of p53 has enabled the 
development of new drugs for research and for therapeutic application. Other recently 
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identified non-MDM-targeting negative regulators of p53, including PIRH2, COP1 and 
TRIM24, also appear promising as small molecule inhibitors (Allton et al., 2009; Dornan 
et al., 2004; Leng et al., 2003). Assessment of the mechanisms and efficacy of these 
agents in murine models that overexpress PIRH2, COP1 or TRIM24 is likely to generate 
new insights.  New and novel p53 regulators, some of them even cancer type-specific, 
will likely be identified in the near future from ongoing cancer genome DNA sequencing 
efforts and searches for mutual exclusivity with p53 aberrations.  Finally, the 
transcriptional p53 targets HAUSP and WIP1 that stabilize MDM2 protein, thus creating 
a regulatory feedback loop, are natural targets for future therapeutic inhibition in 
cancers where one of them is amplified (e.g. invasive breast cancer or pancreatic 
neuroendocrine tumors; TCGA database)(Hu et al., 2010; Jiao et al., 2011).  In regards 
to gene therapy, future work and improvement of technology e.g. CRSPR/CAS9 or the 
use of engineered viruses may solve the problems associated with traditional 
approaches (Vannucci, Lai, Chiuppesi, Ceccherini-Nelli, & Pistello, 2013).  Despite the 
dwindling number of gene therapy trials following the dramatic setbacks caused by the 
development of deadly leukemia in 9 out of 9 pediatric patients after viral gene therapy 
for X-linked severe combined immunodeficiency (Hacein-Bey-Abina et al., 2003), site-
specific, targeted integration of virally delivered genes into the genome of patient cells is 
an active area of research. Newly engineered viruses derived from the lentivirus HIV 
and the adeno-associated virus (AAV) which belongs to the parvovirus family are 
potential alternatives (Gil-Farina & Schmidt, 2016).  Finally, the advent of 
CRISPR/CAS9 technology allowing for gene insertion at defined sites in the genome 
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may overcome the oncogenicity observed with classic viral approaches (Cong et al., 
2013). 
It is remarkable how technological and scientific developments in cancer research are 
mirrored in the evolution of drugs targeting a single pathway: that of the p53 tumor 
suppressor.  In the future we expect that basic research into p53 and its direct and 
indirect regulators will continue to generate insights that inspire academia and pharma 
companies to develop new, improved therapeutics for cancer patients. 
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